Mike Serrano-Wu

A biotech entrepreneur excited to learn something new.

[Mike Serrano-Wu @PapaSWu]

Excited to kick off American Diabetes Month and grateful to @AmDiabetesAssn for building awareness and community!
https://t.co/PTirNXV6Ip

[AnjiPharmaUS @AnjiPharmaUS]

November is #AmericanDiabetesMonth – how much do you know about metformin and glucose management in chronic kidney disease? Check back throughout this month and take part in our quiz to build awareness about #T2D and #CKD!

[AnjiPharmaUS @AnjiPharmaUS]

November is #AmericanDiabetesMonth – how much do you know about metformin and glucose management in chronic kidney disease? Check back throughout this month and take part in our quiz to build awareness about #T2D and #CKD!

[Mike Serrano-Wu @PapaSWu]

@marklxu1 @JLin7 and appreciate the @Jlin7 swag!

[AnjiPharmaUS @AnjiPharmaUS]

We’re thrilled to announce that Anji and Population Health Partners have entered into a strategic collaboration to accelerate development of our two lead clinical assets ANJ900 (delayed-release #metformin) and ANJ908 (pradigastat).Read more here https://t.co/jMlcdXC4c9 #T2D #CKD

[Nancy Serrano-Wu @NancySerranoWu]

So this is happening!!! 🤩🎉🍾

I’m beyond grateful to @rabower and her team for including me in their project about cultural representation in crossword puzzles. 📽️❤️🇨🇦

https://t.co/SaJBytPNTy

[Mike Serrano-Wu @PapaSWu]

Check out this @biorxivpreprint paper highlighting intestinal glucose clearance as a major mechanism for #metformin’s glucose-lowering effects. This affirms our approach to develop ANJ900 and restore metformin access to #T2D patients with advanced #CKD: https://t.co/eUpTSdd9kM

[Mike Serrano-Wu @PapaSWu]

Click here to donate and thx for your support https://t.co/1PZtNPWy0P

[Mike Serrano-Wu @PapaSWu]

@PanMass is Aug 6th and 7th! 100% of proceeds go to patient care and research at @DanaFarber. Here are some of the riders I've met - who's riding this year??

[Mike Serrano-Wu @PapaSWu]

@JohnKerry in 2019

[Mike Serrano-Wu @PapaSWu]

@metabymatt @NancySerranoWu small world, look forward to a Viking theme from one of you

[AnjiPharmaUS @AnjiPharmaUS]

#DYK #metformin is the most widely prescribed drug to treat patients with #T2D and was added to WHO’s list of essential medicines in 2011. Its major benefits
include improved glycemic profile and reduced cardiovascular-associated mortality. Learn more: https://t.co/zFxPIfGkJh

[AnjiPharmaUS @AnjiPharmaUS]

May is #MentalHealthAwarenessMonth. At Anji, we prioritize our team’s work-life balance and recognize that mental health is essential to overall health and well-being. Join us #Together4MH and take action: https://t.co/sHRvsiMcSs #MHAM

[AnjiPharmaUS @AnjiPharmaUS]

We’re sending our thoughts and support to our team in Shanghai as the city remains locked down amid Covid surge. #OneAnji

[AnjiPharmaUS @AnjiPharmaUS]

We would like to welcome Doug Daniels to the #Anjiverse as our new Head of Biologics. Doug has over 20 years of experience in protein science and engineering for the discovery of both biologic and low molecular weight therapeutics. Welcome to the team, Doug!

[AnjiPharmaUS @AnjiPharmaUS]

Inspired by the Anji bridge, Anji translates to “safe crossing,” a term that captures our free exchange of innovative science and ideas. United by a pioneering spirit, we prioritize high-value therapies with human evidence that they work to improve #patientoutcomes

[AnjiPharmaUS @AnjiPharmaUS]

This #NationalKidneyMonth we reflect on this year's theme of #KidneyHealthforAll & the continued efforts to increase awareness of #CKD. Our mission is to expand treatment options for patients with Type 2 diabetes, which is 1 of 4 key risk factors for CKD

[AnjiPharmaUS @AnjiPharmaUS]

Today we announce the appointment of Ulrike Rauh, Ph.D., as our first VP, Oncology. Prior to Anji, Dr. Rauh led international teams and asset development at Bayer. She will lead the development of our #oncology pipeline as we work to potentially restore the brake on #cancer.

[BioCentury @BioCentury]

With $70M in new funding, @AnjiPharmaUS is developing clinical programs for #diabetes and constipation via a "dynamic equity" model based around joint ventures. An Emerging Company Profile by BioCentury's @BioBonanos https://t.co/bT6an9wVuE

[Mike Serrano-Wu @PapaSWu]

Pretty awesome to see Ph3 and Ph2 trials get underway, with new clinical assets gearing up for '22 @AnjiPharmaUS https://t.co/Fdmt2mQFIa